Pear Bio
Pear Bio uses functional precision medicine to develop therapies for hard-to-treat cancers
TreatmentBetaUnited States
See the full profile
The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join End Cancer to request access.
Company info
- Countries of Operation
- United Kingdom
- Founding Year
- 2017
- Number of Employees
- 6–10
Company overview
- Full Description
- Pear Bio is a Boston and London-based AI-enabled biotech company. We develop functional precision medicine-guided therapeutics for patients with hard-to-treat cancers. We take clinical data, tumor biopsies and blood from cancer patients to build a biobank. We find new targets with multi-omics. Once we generate candidate molecules, we test their efficacy directly on patient tumor samples using our clinically-validated immune microtumors to optimize disease positioning and patient selection. Our lead program is a selective, best-in-class CDK12 inhibitor with high efficacy in HER2 low breast cancer and other solid tumors. We have a development candidate with strong animal efficacy data (100% response rate in mouse CDX study, 67% response rate on clinically-relevant treatment-resistant breast cancer PDX models) and optimized selectivity, safety, PK and other ADME properties, with a 1 year timeline to first-in-human studies. Our 2nd program is a first-in-class VSIG4 antibody for solid tumors with immunosuppressive tumor microenvironments.
- Areas of focus
- Biotech / AI / Breast cancer / Solid tumors
- Problem Statement
- Cancers stop responding to treatment through resistance mechanisms. Using the right treatment or combination of treatments at the right time for the right patient is critical. However, precision medicine is introduced very late into the drug discovery and development process; often in a manner that is rushed and not thorough enough to optimize patient selection. This results in less than 25% of Phase 2 cancer drugs getting FDA approval.
- Solution Overview
- Pear Bio uses patient samples and data in a functional precision medicine platform from the very start of the drug discovery process. Patient tumor samples are analyzed for new therapeutic targets, and candidate therapies are testing on live patient cells in the lab to verify their efficacy and synergy in combination therapies. Multi-omics is used to match patients and populations to optimal therapies early in the drug discovery and development process, creating a clearer picture of how to run clinical trials with higher success rate. This process has resulted in the internal development of a best-in-class CDK12 inhibitor for treatment-resistant HER2 low breast cancer and other solid tumors.
Product & IP
- Product Description & Features
- Functional precision medicine platform: predicts patient response to treatments and combination therapies by testing the reaction of tumor samples and immune cells to treatments using 3D live-cell microscopy and computer vision. Multi-omics supports target identification for new therapies through to patient selection with predictive biomarkers/companion diagnostics. PB301: best-in-class CDK12 inhibitor that is the first and only molecule to demonstrate CDK12 expression-dependent response. PB301 has achieved a 100% response rate in mouse CDXs and a 67% response rate in treatment-resistant CDK12+ breast cancer PDXs. VSIG4 antibodies: first-in-class VSIG4 antibodies for immunosuppressed solid tumors.
- Regulatory Approvals
- None yet
- Patents
- Granted · Functional precision medicine platform (4 patents granted) / Pending · CDK12 inhibitors
Looking for
- What are you looking for besides funding?
- Connections to pharma (licensing/partnering) and hospitals (clinical trials).
Team
- Core Team Members
- Duleek Ranatunga · CEO / Matt Williams · CMO / John Curran · COO
Interested in this innovator?
Send a short message. We’ll pass it to Pear Bio with your name and email, so they can reply.
Request an introduction
Create an account or log in to send this request. Already a member? Log in
Introductions to innovators are open to innovators, investors, mentors and corporates.